Table 1.
Clinical characteristics of patients
| Total | End-pointa | No end-pointa | p-value | |
|---|---|---|---|---|
| N = 522 | N = 201 | N = 321 | ||
| Age, years | 82.1 ± 8.7 | 84.2 ± 7.4 | 80.8 ± 9.2 | < 0.001 |
| Female sex | 298 (57.1%) | 123 (61.2%) | 175 (54.5%) | 0.1 |
| Etiology | 0.3 | |||
| IHD | 150 (28.7%) | 45 (22.4%) | 105 (32.7%) | |
| Dilated CM | 9 (1.7%) | 3 (1.5%) | 6 (1.9%) | |
| Hypertensive CM | 207 (39.7%) | 85 (42.3%) | 122 (38.0%) | |
| Alcoholic CM | 7 (1.3%) | 2 (1.0%) | 5 (1.6%) | |
| Valvular disease | 69 (13.2%) | 31 (15.4%) | 38 (11.8%) | |
| Other | 80 (15.4%) | 35 (17.4%) | 45 (20.0%) | |
| LVEFa | 55.8% ± 14 | 56.6% ± 14.2 | 55.4% ± 13.9 | 0.4 |
| NYHA functional class | 0.002 | |||
| I | 8 (1.5%) | 1 (0.5%) | 7 (2.2%) | |
| II | 198 (37.9%) | 63 (31.3%) | 136 (42.4%) | |
| III | 306 (58.6%) | 134 (66.7%) | 175 (54.5%) | |
| IV | 6 (1.1%) | 3 (1.5%) | 3 (0.9%) | |
| Diabetes | 274 (52.4%) | 114 (56.7%) | 160 (49.8%) | 0.1 |
| non insulin-dependent | 157 (30.1%) | 64 (31.8%) | 93 (29.0%) | |
| insulin-dependent | 117 (22.4%) | 50 (24.9%) | 67 (20.9%) | |
| Hypertension | 468 (89.7%) | 184 (91.5%) | 284 (88.5%) | 0.3 |
| COPD | 126 (24.1%) | 54 (26.9%) | 72 (22.4%) | 0.3 |
| Renal failure | 411 (78.7%) | 173 (86.1%) | 238 (74.1%) | 0.001 |
| Anaemia | 341 (65.3%) | 141 (70.1%) | 200 (62.3%) | 0.07 |
| Charlson comorbidity index | 5.6 ± 2.2 | 6.1 ± 2.2 | 5.3 ± 2.1 | < 0.001 |
| Barthel index | 70.5 ± 25.4 | 63.6 ± 26.5 | 74.7 ± 23.7 | < 0.001 |
| Core Readmission risk | 26.3% ± 5.2 | 27.0% ± 5.1 | 25.8% ± 5.2 | 0.009 |
| Urea, mg/dL | 90.8 ± 49.4 | 107.2 ± 56.2 | 80.5 ± 41.8 | < 0.001 |
| Creatinine, mg/dL | 1.4 (1.1–2.0) | 1.5 (1.2–2.1) | 1.8 (1.0–1.79) | < 0.001 |
| Hemoglobin, g/dL | 11.7 ± 1.6 | 11.5 ± 1.6 | 11.9 ± 1.7 | 0.01 |
| Sodium, mmol/L | 137.3 ± 3.8 | 136.9 ± 4.3 | 137.5 ± 3.5 | 0.08 |
| NTproBNP, ng/L | 2770 (1245–5843) | 3900 (1695–7160) | 2170 (1025–4635) | < 0.001 |
| ST2, ng/mL | 42.7 (30.9–63.8) | 54.6 (36.7–79.3) | 37.6 (29.1–52.3) | < 0.001 |
| CA125b, U/ml | 47 (22.4–101.1) | 57.4 (26.7–131.4) | 39.2 (20.2–90.2) | 0.001 |
| Hs-TnIb, ng/L | 23.6 (12.2–61-2) | 28.5 (14.8–67.5) | 21.9 (10.4–57.8) | 0.007 |
aComposite end-point all-cause death or heart failure hospitalization at one year
bAvailable in 466 patients
CM cardiomyopathy, IHD ischemic heart disease, LVEF left ventricular ejection fraction, NYHA New York Heart Association, COPD Chronic obstructive pulmonary disease, CA125 Cancer antigen 125, NTproBNP N-terminal pro-brain natriuretic peptide; hs-TnI high sensitivity troponin I, ST2 Interleukin-1 receptor-like 1